CCA
SURF

Catalyst Capital Advisors’s Surface Oncology, Inc. Common Stock SURF Stock Holding History

Catalyst Capital Advisors’s Portfolio SURF Stock Details SURF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-440
Closed -$7K – 551
2018
Q2 		$7K Buy
+440
New +$6.37K ﹤0.01% 412

Other funds holding SURF

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Catalyst Capital Advisors's SURF Position: Q3 2018 in Review

Catalyst Capital Advisors sold out of Surface Oncology, Inc. Common Stock (SURF) in Q3 2018, closing a stake of 440 shares — an estimated $7K sold.

Catalyst Capital Advisors first reported a position in SURF in Q2 2018 and held it in 1 quarter. The position peaked at $7K in Q2 2018. 43 funds tracked by Wall St. Rank hold SURF as of Q3 2018.

  • Catalyst Capital Advisors reported no remaining Surface Oncology, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Catalyst Capital Advisors sold 440 Surface Oncology, Inc. Common Stock shares in Q3 2018, an estimated $7K.
  • Catalyst Capital Advisors first reported a position in Surface Oncology, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Catalyst Capital Advisors's Surface Oncology, Inc. Common Stock position peaked at $7K in Q2 2018.
  • 43 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q3 2018.

Based on Catalyst Capital Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.